---
title: "Congress Pushes Back on Plan for Political Commission to Review NIH Grants"
id: "stat-news-0-stat-members-of-congress-push-back-on-plan-to-create-a-commission-of-political"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-0-stat-members-of-congress-push-back-on-plan-to-create-a-commission-of-political"
content_type: "clinical_feed_article"
specialty: "General"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/09/21/trump-plan-for-commission-to-review-nih-grants-push-back/?utm_campaign=rss"
published_at: "2026-09-21T22:17:21.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Congress Pushes Back on Plan for Political Commission to Review NIH Grants
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-0-stat-members-of-congress-push-back-on-plan-to-create-a-commission-of-political
- **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/09/21/trump-plan-for-commission-to-review-nih-grants-push-back/?utm_campaign=rss)
- **Published At:** 2026-09-21T22:17:21.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Tensions rose after reports that White House Office of Management and Budget (OMB) director **Russell Vought** sought an executive order to create a commission that would review all **NIH** grants. - The plan reportedly emerged from a contentious White House meeting; President Trump is said to have directed Vought to draft the order after NIH Director **Jay Bhattacharya** declined to cut funding for Harvard researchers. - Media reports indicate the proposed board would include Vought and Bhattacharya and would be required to reach unanimous decisions on grant approvals. - Several members of Congress have voiced strong opposition to the reported proposal, signaling increased scrutiny and pushback on expanded White House control over federal biomedical research funding. - Details of the proposal’s membership, formal scope, legal authority, implementation timeline, and current status were not reported in the source article. - The STAT report notes parts of the story are behind a STAT+ paywall; additional details and reporting were described as exclusive content for subscribers. - Coverage cited other outlets, including The Washington Post and Politico, as reporting elements of the plan; STAT reporters Anil Oza and Chelsea Cirruzzo byline the piece. - The report frames the development as part of broader tensions over White House influence on federal research funding but does not provide further documentary evidence or official White House or NIH responses in the published excerpt.
## Clinical Analysis & Structured Key Points
OMB head Vought pushes for commission to review NIH grants | STAT Skip to Main Content STAT Plus Politics Members of Congress push back on plan to create a commission of political appointees to review NIH grants Trump reportedly asked his OMB director to draft an executive order in a White House meeting Manage alerts for this article Save this story for later Share this article Russell Vought, director of the White House Office of Management and Budget. Finn Gomez/Getty Images By Anil Oza and Chelsea Cirruzzo Sept. 21, 2026 Anil Oza [email protected] Anil Oza is a general assignment reporter at STAT focused on the NIH and health equity. You can reach him on Signal at aniloza.16. Chelsea Cirruzzo [email protected] Chelsea covers the Department of Health and Human Services with a particular focus on power and influence at the top. Confidential tips can be sent via Signal at chelseacirruzzo.42. Tensions over increased White House control of federal biomedical research funding escalated in recent days, with several members of Congress voicing strong opposition after news leaked about a plan to create a panel of political appointees to sign off on all National Institutes of Health grants. In what has been reported to be a contentious meeting at the White House on Friday, Russell Vought, the head of the White House Office of Management and Budget, pushed for an executive order creating a commission that would review all NIH grants, according to The Washington Post . President Trump, reportedly angry that NIH Director Jay Bhattacharya had refused to cut funding for Harvard researchers, directed Vought to draft the order. Advertisement Politico reported Vought and Bhattacharya would serve on the proposed board, which would be required to reach unanimous decisions on grants. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+. Already have an account? Log in Individual plans Group plans Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In Donald Trump , NIH , STAT+ , White House Submit a correction request Reprints Anil Oza General Assignment Reporter Anil Oza is a general assignment reporter at STAT focused on the NIH and health equity. You can reach him on Signal at aniloza.16. Chelsea Cirruzzo Washington Correspondent Chelsea covers the Department of Health and Human Services with a particular focus on power and influence at the top. Confidential tips can be sent via Signal at chelseacirruzzo.42. Newsletter The latest updates in federal health agencies, research institutes, and U.S. policy Please enter a valid email address. Sign Up Your data will be processed in accordance with our Privacy Policy and Terms of Service . You may opt out of receiving STAT communications at any time. Recommended Opinions+ Opinions+ September 21, 2026 STAT Plus: The NIH budget should be $100 billion per year Politics Politics September 21, 2026 STAT Plus: Can RFK Jr. help GOP win the midterms? Iowa is a test Advertisement Business Business September 18, 2026 STAT Plus: Trump touts pharma deals to offer cheaper drugs to state Medicaid programs Politics Politics September 17, 2026 Kennedy announces new effort to speed up autism diagnoses Health Health September 17, 2026 Kennedy renews attacks on vaccines at Children’s Health Defense conference Subscriber Picks
## Related Clinical Research

- [CoRoPINN: Cognitive Region-Optimized PINNs for More Accurate PDE Solving](https://medichelpline.com/clinical-feed/plos-one-20-coropinn-cognitive-region-optimized-physics-informed-neural-networks.md)
- [Design and testing of FFF-printed PLA honeycomb sandwich panels for flexural strength and mass eff](https://medichelpline.com/clinical-feed/plos-one-1-experimental-investigation-and-multi-response-design-of-fff-printed-pla.md)
- [Burden and adherence to long-term anti-VEGF intravitreal injections for retinal disease: qualitati](https://medichelpline.com/clinical-feed/bmj-open-11-treatment-burden-and-adherence-in-adults-receiving-long-term-anti-vegf.md)
- [Spatio-temporal imaging and acute manipulation of endogenous Yap1 in medaka using a Yap1-mGreenLan](https://medichelpline.com/clinical-feed/biorxiv-17-spatio-temporal-visualisation-and-manipulation-of-endogenous-yap1-in-medaka.md)
- [Non-retinoid RBP4 antagonist AKR-XI-85 as a candidate therapy for Stargardt disease](https://medichelpline.com/clinical-feed/biorxiv-19-a-non-retinoid-triazolopyrimidine-rbp4-antagonist-for-the-treatment-of.md)

## Navigation
- [← Back to General Feed](https://medichelpline.com/clinical-feed/general.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.